Market-Based Licensing for HPV Vaccines in Developing Countries
Boston University School of Law
Aaron S. Kesselheim
Brigham and Women's Hospital/Harvard Medical School; Harvard University - Edmond J. Safra Center for Ethics
January 1, 2008
Health Affairs, Vol. 27, No. 1, 2008
Human papillomavirus (HPV) vaccines hold great promise for preventing cervical cancer, but 93 percent of mortality worldwide occurs in low- and middle-income countries, where high vaccine costs can restrict dissemination. Current models for promoting international access to health care innovations include differential pricing, advance market commitments, and voluntary and compulsory licensing. Some of these mechanisms have been effective, but much room for improvement remains. We discuss the usefulness of a new type of license that uses market forces to lower prices through generic competition in low- and middle-income countries while ensuring that pharmaceutical companies are appropriately reimbursed for their research and development.
Number of Pages in PDF File: 14
Keywords: Compulsory license, HPV vaccine, generic open license, access to vaccinesAccepted Paper Series
Date posted: November 22, 2009 ; Last revised: April 16, 2013
© 2013 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo7 in 0.375 seconds